Summary
The product Turinabol 10 mg, manufactured by Hilma Biocare, was analyzed to verify its composition and potency. The sample, identified by batch number 062442, was tested by Janoshik Analytical, a laboratory known for its expertise in pharmaceutical quality testing. The analysis confirmed the presence of Turinabol with a measured concentration of 10.01 mg per tablet, reflecting a 0.1% variance above the label claim. These findings indicate that the product is dosed with exceptional accuracy.
The testing process was initiated on 21 March 2024, with the sample received on 4 April 2024, and the analysis completed on 9 April 2024. As the sample was submitted and paid for by the manufacturer, Hilma Biocare, the results warrant careful scrutiny. This report serves an educational purpose, aiming to help consumers make informed decisions about the accuracy and consistency of anabolic steroid products.
Detailed Report
Product Overview
- Manufacturer: Hilma Biocare
- Product Name: Turinabol
- Active Ingredient: Turinabol
- Batch Number: 062442
- Expiration Date: Not provided
- Delivery Method: Oral (tablet)
Sample Acquisition and Testing
- Task Number: #40584
- Testing Ordered: 21 March 2024
- Sample Received: 4 April 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Hilma Biocare (Manufacturer)
- Analysis Paid For By: Hilma Biocare (Manufacturer)
Testing Results
- Specification: 10 mg/tablet (as stated on the label)
- Measured Concentration: 10.01 mg/tablet
- Accuracy: 100.1% (0.1% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/40584_BG4TIZ5ANYH9
- Originally Published: https://thinksteroids.com/community/posts/3263600/
Evaluation of Manufacturer-Funded Testing
This test report was both submitted and funded by the manufacturer, Hilma Biocare, which necessitates a critical evaluation of the findings. Manufacturer-funded testing may involve selective sample submission or implicit pressure on the laboratory. However, the credibility of Janoshik Analytical, along with its history of transparency and reliable analysis, adds confidence to the results. Cross-referencing with third-party testing, when available, is recommended to further substantiate the findings.
Conclusion
The analysis demonstrates that Turinabol 10 mg from Hilma Biocare is dosed with remarkable precision, with a measured concentration of 10.01 mg/tablet, exceeding the label claim by a negligible margin. This report offers valuable insights for educational and harm reduction purposes, encouraging informed decision-making among consumers. Independent validation would further strengthen the confidence in these results.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
